Amarin Receives Recommendation From Spanish Drug Pricing Committee For National Reimbursement Of VAZKEPA In Spain
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation's drug VAZKEPA has received a positive recommendation from Spain's Drug Pricing Committee for national reimbursement. This marks the final step in the reimbursement process in Spain, following months of negotiations between the Spanish Ministry of Health, regional authorities, and Amarin. The company expects eligible cardiovascular patients to be able to access VAZKEPA under national reimbursement from September 1, 2023.
July 25, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's VAZKEPA has received a positive recommendation for national reimbursement in Spain. This could potentially increase the drug's accessibility and sales in the country, positively impacting Amarin's revenues.
The positive recommendation for national reimbursement of VAZKEPA in Spain is a significant milestone for Amarin. It could lead to increased sales of the drug in the country, as more patients will be able to afford it. This could, in turn, boost Amarin's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100